MVRIX participated in the 2nd Cell&Gene Tech Investment Forum (CGTI Forum) hosted by the Association of Regenerative Medicine (CARM) and CHA Bio Group.

CEO Sang Won Jung shared industry trends and engaged in active networking with major companies in the field of cell and gene therapy (CGT), and also delivered an IR presentation on MVRIX's Grab antibody-based precision targeted delivery platform.